Specifications tableSubject areaInternal and Cardiovascular MedicineMore specific subject areaOral anticoagulation in patients aged 90 years or older with atrial fibrillationType of dataTables and FiguresHow data was acquiredDocument analysis were retrospectively and prospectively collectedData formatRaw, analyzedExperimental factorsPatients aged 90 years or older with non-valvular atrial fibrillation treated with oral anticoagulants were included. Patients on direct oral anticoagulants were derived from a prospective multicentre registry while patients on vitamin-K antagonists from the Anticoagulation Clinic of the University Hospital in Perugia.Experimental featuresData on ischemic stroke and systemic embolism, major bleeding, permanent discontinuation and all-cause death were i) prospectively collected in patients treated with direct oral anticoagulants through every-6-month visits and ii) retrospectively collected since the start of anticoagulant treatment or when the patient became 90 years of age or older in nonagenarians treated with vitamin-K antagonists\
A time-to-event analysis taking competing risk by death into account was performed.Data source locationDepartment of Internal and Cardiovascular Medicine, Perugia, Italy.Data accessibilityThe data are with this article.Related research articleGiustozzi M, Vedovati MC, Verso M, Scrucca L, Verdecchia P, Conti S et al. Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study. Int J Cardiol 2018; in press [@bib1].**Value of the data**•The data presented in this article provide original information and increase knowledge on the use of oral anticoagulants in patients aged 90 years or older with atrial fibrillation.•The data can be used by clinicians and researchers to generate hypothesis for further studies and as reference.•These data could support the decision making process on the use of oral anticoagulation in patients aged 90 years or older.

1. Data {#sec1}
=======

The dataset of this article comprises five data files that were generated from further analysis of 546 patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants.

[Fig. 1](#fig1){ref-type="fig"} shows the selection of the population with the number of patients divided according to type \[direct oral anticoagulants (DOAC) or vitamin-K antagonist (VKA)\] and duration (already on anticoagulant or naïve) of oral anticoagulation. The time course of ischaemic stroke/TIA and systemic embolism (panel A) and for major bleeding (panel B) according to the presence of outcome predictors are given in [Fig. 2](#fig2){ref-type="fig"}. Main causes of permanent discontinuation in the overall population and according to the type of anticoagulation received are shown in [Table 1](#tbl1){ref-type="table"}. The same table reports the percentages of patients that discontinued anticoagulants or died and the annual incidence rates of discontinuation and death. Data on hazard ratios and subdistribution hazard ratios of main predictors for permanent discontinuation are reported in [Fig. 3](#fig3){ref-type="fig"}. [Table 2](#tbl2){ref-type="table"} shows data on comparisons of sub-group of patients, specifically i) oral anticoagulant naïve users vs. long-term oral anticoagulant users and ii) patients on anticoagulant therapy for less than 2 years (new users) vs. patients on anticoagulant therapy for more than 2 years. Here, we report data in the overall population and according to treatment group.Fig. 1Flow-chart of patients.Fig. 1Fig. 2Time course of and main predictors for ischaemic stroke/TIA/systemic embolism and major bleeding.Fig. 2Table 1Main causes of permanent discontinuation and of all-cause death in the overall population and according to the type of anticoagulation.Table 1VariableAll patients (n = 546)VKAs patients (n = 301)DOACs patients (n = 245)Permanent discontinuation, n (%)957223(17%; 10.4% pts-y)(24%; 10.9% pts-y)(9%; 8.9% pts-y)Main causes Bleeding413011 Physician/patient\'s decision20146 High risk of falls550 Poor adherence550 Cancer440 Renal failure202 Unknown14122 Other422Death, n (%)1469749(16.0% pts-y)(14.8% pts-y)(19.1% pts-y) Fatal bleeding954 Fatal ischemic stroke211 Fatal AMI312Fig. 3Main predictors for permanent discontinuation.Fig. 3Table 2Data on comparisons of sub-group of patients: i) anticoagulation naïve vs. anticoagulation non-naïve patients, ii) new users vs. non-new users.Table 2Outcome eventIschaemic stroke/TIA/SEMajor bleedingAll-cause deathPermanent discontinuationSHR, 95% CISHR, 95% CISHR, 95% CISHR, 95% CIAnticoagulation naïve1.85 (0.55--6.24)1.24 (0.47--3.31)1.23 (0.52--2.93)1.63 (0.81--3.28)DOAC[a](#tbl2fna){ref-type="table-fn"} Anticoagulation naïve0.19 (0.03--1.40)1.12 (0.27--4.60)0.62 (0.25--1.54)0.76 (0.26--2.24)New users1.37 (0.51--3.71)1.62 (0.78--3.36)1.10 (0.68--1.79)1.10 (0.66--1.82)DOAC[a](#tbl2fna){ref-type="table-fn"} new users0.27 (0.04--1.72)0.86 (0.24--3.00)0.67 (0.33--1.38)1.07 (0.40--2.85)[^1]

2. Experimental design, materials and methods {#sec2}
=============================================

Data on DOAC patients were derived from a multicentre prospective Italian registry of atrial fibrillation patients [@bib2] while data on VKA patients were retrospectively derived from the database of the Anticoagulation Clinic of Perugia. For both group, data were collected since time of anticoagulation prescription or since the patient became 90 years old. Follow-up was performed every 6 months by visits or telephone contacts in the DOAC group while follow-up was retrospectively retrieved in the VKA group.

Due to the expected high mortality of study patients, we performed a time-to-event analyses taking death as competing risk. We calculated the cumulative incidences and the risks of a) ischemic stroke/TIA and systemic embolism; b) major bleeding; c) permanent discontinuation. Data were reported as sub-distribution hazard ratios (SHR) and 95% confidence interval. Statistical analysis was performed using R 3.5.0.
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[^1]: Anticoagulation naive patients treated with DOACs compared with anticoagulation naive patients treated with VKAs.
